These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38951303)

  • 1. Beyond quadruple therapy: the potential roles for ivabradine, vericiguat, and omecamtiv mecarbil in the therapeutic armamentarium.
    Shoji S; Mentz RJ
    Heart Fail Rev; 2024 Jun; ():. PubMed ID: 38951303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis.
    Pagnesi M; Baldetti L; Aimo A; Inciardi RM; Tomasoni D; Vizzardi E; Vergaro G; Emdin M; Lombardi CM
    J Clin Med; 2022 Jan; 11(2):. PubMed ID: 35054042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond Quadruple Therapy and Current Therapeutic Strategies in Heart Failure with Reduced Ejection Fraction: Medical Therapies with Potential to Become Part of the Therapeutic Armamentarium.
    Kourek C; Briasoulis A; Papamichail A; Xanthopoulos A; Tsougos E; Farmakis D; Paraskevaidis I
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial.
    Felker GM; Solomon SD; Claggett B; Diaz R; McMurray JJV; Metra M; Anand I; Crespo-Leiro MG; Dahlström U; Goncalvesova E; Howlett JG; MacDonald P; Parkhomenko A; Tomcsányi J; Abbasi SA; Heitner SB; Hucko T; Kupfer S; Malik FI; Teerlink JR
    JAMA Cardiol; 2022 Jan; 7(1):26-34. PubMed ID: 34643642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.
    Lewis GD; Voors AA; Cohen-Solal A; Metra M; Whellan DJ; Ezekowitz JA; Böhm M; Teerlink JR; Docherty KF; Lopes RD; Divanji PH; Heitner SB; Kupfer S; Malik FI; Meng L; Wohltman A; Felker GM
    JAMA; 2022 Jul; 328(3):259-269. PubMed ID: 35852527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials.
    Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Adams KF; Anand I; Arias-Mendoza A; Biering-Sørensen T; Böhm M; Bonderman D; Cleland JGF; Corbalan R; Crespo-Leiro MG; Dahlström U; Echeverria Correa LE; Fang JC; Filippatos G; Fonseca C; Goncalvesova E; Goudev AR; Howlett JG; Lanfear DE; Lund M; Macdonald P; Mareev V; Momomura SI; O'Meara E; Parkhomenko A; Ponikowski P; Ramires FJA; Serpytis P; Sliwa K; Spinar J; Suter TM; Tomcsanyi J; Vandekerckhove H; Vinereanu D; Voors AA; Yilmaz MB; Zannad F; Sharpsten L; Legg JC; Abbasi SA; Varin C; Malik FI; Kurtz CE;
    Eur J Heart Fail; 2020 Nov; 22(11):2160-2171. PubMed ID: 32985088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF.
    Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Legg JC; Büchele G; Varin C; Kurtz CE; Malik FI; Honarpour N
    JACC Heart Fail; 2020 Apr; 8(4):329-340. PubMed ID: 32035892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis.
    Ameri P; De Marzo V; Zoccai GB; Tricarico L; Correale M; Brunetti ND; Canepa M; De Ferrari GM; Castagno D; Porto I
    Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 8(8):768-776. PubMed ID: 34928347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.
    Liu LC; Dorhout B; van der Meer P; Teerlink JR; Voors AA
    Expert Opin Investig Drugs; 2016; 25(1):117-27. PubMed ID: 26587768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil.
    Kaplinsky E; Mallarkey G
    Drugs Context; 2018; 7():212518. PubMed ID: 29707029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Treatment of Heart Failure: Recent Advances.
    Chan JCH; Siddiqui A
    Curr Cardiol Rev; 2024; 20(2):29-38. PubMed ID: 38284706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial Experience of Vericiguat Treatment in Patients with Heart Failure and Reduced Ejection Fraction.
    Nakamura M; Imamura T; Kinugawa K
    J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
    Kang C; Lamb YN
    Am J Cardiovasc Drugs; 2022 Jul; 22(4):451-459. PubMed ID: 35624347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trial.
    Docherty KF; McMurray JJV; Claggett BL; Miao ZM; Adams KF; Arias-Mendoza A; Cleland JGF; Diaz R; Echeverria Correa LE; Felker GM; Fonseca C; Li J; Metra M; Sliwa-Hahnle K; Solomon SD; Vandekerckhove HJ; Vinereanu D; Voors AA; Heitner SB; Kupfer S; Malik FI; Meng L; Teerlink JR
    Eur J Heart Fail; 2023 Feb; 25(2):248-259. PubMed ID: 36597719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetic Properties of Omecamtiv Mecarbil in Healthy Subjects and Patients With Heart Failure With Reduced Ejection Fraction.
    Chen PW; Trivedi A; Lee E; Dutta S; Ahamadi M
    J Cardiovasc Pharmacol; 2022 Apr; 79(4):539-548. PubMed ID: 34983909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the Management of Heart Failure with Reduced Ejection Fraction; The Role of SGLT2is, ARNI, Myotropes, Vericiguat, and Anti-inflammatory Agents: A Mini-review.
    Vrachatis DA; Papathanasiou KA; Giotaki SG; Raisakis K; Kaoukis A; Kossyvakis C; Theodorakis A; Pediotidis S; Avramides D; Siasos G; Deftereos S
    Curr Pharm Des; 2023 Mar; ():. PubMed ID: 36927423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure.
    Tondi L; Fragasso G; Spoladore R; Pinto G; Gemma M; Slavich M; Godino C; Salerno A; Montanaro C; Margonato A
    J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):351-356. PubMed ID: 29762337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF.
    Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Biering-Sørensen T; Böhm M; Bonderman D; Fang JC; Lanfear DE; Lund M; Momomura SI; O'Meara E; Ponikowski P; Spinar J; Flores-Arredondo JH; Claggett BL; Heitner SB; Kupfer S; Abbasi SA; Malik FI;
    J Am Coll Cardiol; 2021 Jul; 78(2):97-108. PubMed ID: 34015475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF.
    Lanfear DE; Njoroge JN; Adams KF; Anand I; Fang JC; Ramires F; Sliwa-Hahnle K; Badat A; Burgess L; Gorodeski EZ; Williams C; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon S; Miao ZM; Claggett BL; Heitner SB; Kupfer S; Malik FI; Teerlink JR
    JACC Heart Fail; 2023 May; 11(5):569-579. PubMed ID: 36881396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of omecamtiv mecarbil for heart failure: A systematic review and meta-analysis.
    Alqatati F; Elbahnasawy M; Bugazia S; Ragab KM; Elsnhory AB; Shehata M; Elsayed SM; Fathy MA; Nourelden AZ
    Indian Heart J; 2022; 74(3):155-162. PubMed ID: 35301008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.